Posters
Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - ANCA/FSGS
October 23, 2026 | 10:00 AM - 12:00 PM
Location: Exhibit Hall A, Convention Center
Session Description
Poster Session
Posters
Avacopan Real-World Safety in Adults with ANCA-Associated Vasculitis: AvacoStar Interim Results
Baricitinib Reduces Albuminuria in APOL1-Mediated Kidney Disease: A Pilot Randomized Trial
Nephrin Autoantibodies in Idiopathic Nephrotic Syndrome Represent a Disease Endotype Associated with Good Long-Term Prognosis
Validation of the Klinrisk Machine Learning Model in Patients with FSGS
Rituximab Reduces Specific Antibody Titres in Childhood-Onset Idiopathic Nephrotic Syndrome
Remission Kinetics Drive Kidney Outcomes of Podocytopathies in Adults: Insights from a 12-Year Cohort
Early Initiation of Kidney Replacement Therapy Is Associated with an Increased Risk of Infection-Related Death in ANCA-Associated Vasculitis: A Multicenter Cohort Study (J-CANVAS)
Epidemiology of Primary FSGS (pFSGS): Challenges Defining Incidence and Prognosis
Partial Remission (PR) and FSGS-Specific Partial Remission (FSGSPR)as Surrogate Outcomes for Long-Term Kidney Survival: A Population-Based Study
Characteristics and Progression of Glomerular Disease in Patients with APOL1-Associated Kidney Disease
Primary Anti-C1q-Associated Renal Vasculitis: A Clinicopathologic Case Series
Serum Lipidomic Profiles for Distinguishing Primary FSGS from Minimal Change Disease in Patients with Nephrotic Syndrome
One Year with Avacopan: A Milan Experience in the Treatment of ANCA-Associated Vasculitis
Clinicopathologic Characteristics and Short-Term Outcomes of Medium-Vessel Involvement in ANCA-Associated Vasculitis: A Chinese Cohort Study
Association Between Achievement of Low-Proteinuria Thresholds and Health-Related Quality of Life in FSGS: Pooled DUET and DUPLEX Analysis
Sparsentan in APOL1-Mediated Kidney Disease: A DUPLEX Post Hoc Signal and Trial Roadmap
Cardiovascular Risk Profiling and Protection in ANCA-Associated Glomerulonephritis: Analyses of Risk Factors and Benefit of SGLT2 Inhibition in Real-World Data Sets
APOL1 High-Risk Genotypes and Risk of ESKD in Lupus Nephritis: A Systematic Review and Meta-Analysis
Risk of Disease Progression and Tolerance of Antifibrotic Agents in Patients with ANCA-Associated Pulmonary-Renal Syndrome with Interstitial Lung Disease
Nephrin Antibody-to-IgG Ratio Predicts Relapse-Prone Podocytopathy: A Single-Center, Retrospective, Observational Study
ANCA-Associated Vasculitis with Kidney Involvement at a Tertiary Care Centre: A Retrospective Case Series Characterising Disease Patterns, Histopathological Findings, and Clinical Outcomes
ANCA-Associated Glomerulonephritis: The Qatar Experience
Real-World Effectiveness and Safety of Avacopan in Patients with ANCA-Associated Vasculitis: A Systematic Review and Meta-Analysis
Health Care Resource Use and Economic Burden of ANCA-Associated Vasculitis in the United States
Serum Proteinase 3 Antibody Titers in Primary vs. Secondary ANCA-Associated Glomerulonephritis
ANCA-Negative Relapses in Patients with ANCA-Associated Vasculitis
Rituximab with or Without Avacopan in ANCA-Associated Vasculitis with Severe Kidney Involvement: A Retrospective Comparative Cohort Study
Avacopan in ANCA-Associated Vasculitis with Severe Kidney Disease
Real-World Outcomes with Avacopan in ANCA-Associated Vasculitis: A Single-Center Experience
WAL0921, an Anti-Soluble Urokinase Plasminogen Activator Receptor (suPAR) Monoclonal IgG1 Antibody, Is Safe and Well Tolerated in a Phase 1 Single Ascending Dose (SAD) Study and Reduces Circulating suPAR in Healthy Participants
Epidemiology of FSGS: A Systematic Review of Studies Published from 2020 to 2025
Humanistic Burden of FSGS: Findings from a Systematic Review
Revisiting Remission Definitions in Primary Podocytopathy
Effect of Dialysis on In-Hospital Outcomes in ANCA-Associated Vasculitis
Nephrotic Syndrome Outcomes in Teaching Hospitals: NIS 2017-2018
Intravenous vs. Oral Cyclophosphamide for Minimal Change Disease in Children: A Systematic Review and Meta-Analysis
Recurrent ANCA-Associated Vasculitis Exhibits Impaired Renal but Preserved Systemic Biomarker Recovery
FSGS Not Otherwise Specified, Not HIV-Associated Nephropathy, Predominates in Kidney Biopsy Pathology in a Contemporary Urban HIV Cohort
A Registry-Based Study of Treatment Patterns and Outcomes in Patients with FSGS in the United States
Severe Kidney Involvement and Therapeutic Gaps in Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Mexican Tertiary-Center Cohort
Long-Term Real-World Effectiveness of Ravulizumab Among C5-Inhibitor-Naive Patients with Atypical Hemolytic Uremic Syndrome (aHUS): A Physician-Panel-Based Chart Review Study (aHUS-EXTEND Study)
Application of the Focal, Segmental, Tubular, Interstitial, and Vascular Score and Mayo Clinic Chronicity Score in Idiopathic Membranous Nephropathy: Clinical and Prognostic Value
Correlation Analysis of Kidney Pathology and Clinical Indicators in Patients with Diabetic Nephropathy
Efficacy of SGLT2 Inhibition in Patients with Immune Glomerulopathy
Glucocorticoid (GC)-Associated Conditions in Patients with Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) with Prolonged Moderate-to-High (M/H) Dose GC Use
Patients with Nephrotic Syndrome Who Develop Venous Thromboembolism Have More Significant Long-Term Kidney Function Decline: A Multicenter Retrospective Cohort Study
Immediate Kidney Biopsy Specimen Adequacy Verification with a Portable Digital Microscope
Evaluation of the Complement System in the Pathogenesis and Prognosis of Normocomplementemic Glomerulopathies
Association Between Kidney Biopsy Activity and Chronicity Indices with Kidney Function and Proteinuria in Patients with Lupus Nephritis: A Cross-Sectional Analysis
Humoral Response to SARS-CoV-2 mRNA Vaccination in Nephrology Patients Receiving Immunosuppressive Therapy
Real-World Clinical Outcomes, Patient Outcomes, and Physician Experience with the Eculizumab Biosimilar BEKEMV in Patients with Atypical Haemolytic Uremic Syndrome